Innoviva Owners | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Innoviva Inc.

Innoviva Inc. | Ownership

Companies that own Innoviva Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

BlackRock Fund Advisors

10,828,663

10.67%

558,843

0.01%

06/30/2018

The Vanguard Group, Inc.

6,704,609

6.61%

-442,869

06/30/2018

Sarissa Capital Management LP

4,535,000

4.47%

874,295

11.65%

06/30/2018

Renaissance Technologies LLC

3,390,800

3.34%

1,084,980

0.05%

06/30/2018

Fidelity Management & Research Co.

2,687,293

2.65%

-6,073,058

06/30/2018

SSgA Funds Management, Inc.

2,397,409

2.36%

52,572

06/30/2018

Point72 Asset Management LP

1,926,732

1.9%

1,492,863

0.14%

06/30/2018

Dimensional Fund Advisors LP

1,909,111

1.88%

185,825

0.01%

06/30/2018

Invesco Capital Management LLC

1,857,926

1.83%

541,560

0.02%

06/30/2018

Bank of America, NA (Private Banking)

1,827,698

1.8%

87,697

0.02%

06/30/2018

About Innoviva

View Profile

Address	2000 Sierra Point Parkway Brisbane California 94005 United States
Employees	-
Website	http://www.inva.com
Updated	07/08/2019
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P.